A5064513746- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Immunology Research
- vaccines and immunoinformatics approaches
Beth Israel Deaconess Medical Center
2023-2024
Harvard University
2024
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show NAb titers are substantially lower to but similar slightly higher than other current circulating variants, including EG.5.1, FL.1.5.1. Moreover, against all these variants were vaccinated individuals a history of...
Abstract The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 F486P mutations. rapidly increased in frequency become dominant virus New England. bivalent mRNA vaccine boosters have been shown increase neutralizing antibody (NAb) titers multiple variants, but durability of these responses remains be determined. We assessed humoral cellular immune 30 participants who received performed assays...
Messenger RNA (mRNA) vaccines were highly effective against the ancestral SARS-CoV-2 strain, but efficacy of bivalent mRNA boosters XBB variants was substantially lower. Here, we show limited durability neutralizing antibody (NAb) responses and isotype switching to immunoglobulin G4 (IgG4) following boosting. Bivalent boosting elicited modest XBB.1-, XBB.1.5-, XBB.1.16-specific NAbs that waned rapidly within 3 months. In contrast, induced more robust sustained WA1/2020 suggesting immune...
ABSTRACT The continued evolution of SARS-CoV-2 may lead to evasion vaccine immunity and natural immunity. A highly mutated Omicron variant BA.2.86 has recently been identified with over 30 amino acid changes in Spike compared BA.2 XBB.1.5. As September 4, 2023, 37 sequences from 10 countries, which is likely an underestimate due limited surveillance. ability evade NAbs other currently circulating variants remains unknown. Our data show that NAb responses were lower than but comparable or...
The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and administered to over 200 million people. Prior studies have shown that induces durable neutralizing antibodies (NAbs) increase in coverage of variants time, even absence boosting or infection. Here, we studied humoral responses following vaccination individuals enrolled initial Phase 1/2a trial 2020. Through 8 months post vaccination, serum NAb increased variants, including B.1.351 (Beta)...
Background Neoantigens are promising immunogens for cancer vaccines and often delivered as adjuvanted peptide vaccines. Adenoviral (Ad) vectors have been shown to induce strong CD8 + T cell responses against SARS-CoV-2, Ebola, Zika, but their utility neoantigen delivery remains largely unexplored. In this study, we examine how an Ad-vectored vaccine would impact tumor immunity compared with a vaccine. Methods We generated Ad serotype 26 (Ad26) candidates encoding B16-F10-ovalbumin (OVA)...